Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

DOI Web Site 1 Citations

Description

<jats:p>Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.</jats:p>

Journal

  • Medicina

    Medicina 55 (10), 707-, 2019-10-21

    MDPI AG

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top